Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 3,272 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Progenitor Cells Clear all
Terminated Phase 1Phase 2 Interventional Results available

Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma

NCT04635735
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Ipilimumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 73 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 17, 2026, 11:13 AM EDT
Not listed No phase listed Observational

Translational Approaches to Septic Cardiomyopathy

NCT03252613
View directory record Official record
Conditions
Cardiomyopathies, Sepsis, Septic Shock
Interventions
Not listed
Lead sponsor
Samuel Brown
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Stanford, California • Murray, Utah
Source: ClinicalTrials.gov public record
Updated Dec 24, 2018 · Synced Oct 17, 2026, 11:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

NCT00784823
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib 1 mg/m2, Bortezomib 1.3 mg/m2, Bortezomib 1.6 mg/m2, Melphalan
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 76 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 17, 2026, 11:13 AM EDT
Completed Phase 1Phase 2 Interventional

Allogeneic Human Mesenchymal Stem Cell Infusion vs Placebo in Alcohol Use Disorder and Major Depression.

NCT03265808
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
allogeneic human mesenchymal stem cells (allo-hMSCs), Placebo
Drug
Lead sponsor
Ihsan M Salloum, MD, MPH
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Harlingen, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 17, 2026, 11:13 AM EDT
Completed Phase 2 Interventional Results available

Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

NCT02683525
View directory record Official record
Conditions
Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
Interventions
Sitagliptin
Drug
Lead sponsor
Sherif S. Farag
Other
Eligibility
18 Years to 60 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 17, 2026, 11:13 AM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

NCT02181413
View directory record Official record
Conditions
Multiple Myeloma, Autologous Stem Cell Transplant
Interventions
Ixazomib Citrate, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
6
States / cities
Little Rock, Arkansas • Rochester, Minnesota • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 17, 2026, 11:13 AM EDT
Completed Phase 2 Interventional Results available

Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease

NCT02133924
View directory record Official record
Conditions
Acute Graft Versus Host Disease
Interventions
natalizumab, steroids
Drug
Lead sponsor
John Levine
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
12
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 17, 2026, 11:13 AM EDT
Completed No phase listed Observational

Brilliant Study: Assessing Cognition in Myeloma Patients Undergoing Transplant

NCT03355235
View directory record Official record
Conditions
Stem Cell Transplant Complications
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 17, 2026, 11:13 AM EDT
Completed Phase 2 Interventional Results available

Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma

NCT00278525
View directory record Official record
Conditions
SYSTEMIC SCLERODERMA
Interventions
standard of care, stem cell transplantation
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
Up to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Oct 17, 2026, 11:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)

NCT01392625
View directory record Official record
Conditions
Non-ischemic Dilated Cardiomyopathy
Interventions
Autologous hMSCs, Allogeneic hMSCs
Biological
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years to 95 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 17, 2026, 11:13 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.

NCT00571389
View directory record Official record
Conditions
Solid Tumor, Adult, Healthy Donors, COVID-19 Donors
Interventions
Not listed
Lead sponsor
BioCytics, Inc.
Industry
Eligibility
5 Years and older
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2030
U.S. locations
1
States / cities
Huntersville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 17, 2026, 11:13 AM EDT
Withdrawn Phase 2 Interventional

Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas

NCT04334174
View directory record Official record
Conditions
T Cell Lymphoma
Interventions
Brentuximab Vedotin
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2023 · Synced Oct 17, 2026, 11:13 AM EDT
Completed Phase 3 Interventional

High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas

NCT00078988
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumor
Interventions
filgrastim, carboplatin, etoposide, isotretinoin, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
52
States / cities
Little Rock, Arkansas • Oakland, California • Sacramento, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Oct 17, 2026, 11:13 AM EDT
Completed Not applicable Interventional

Effect of Implanting Allogenic Cytokines Derived From Human Amniotic Membrane (HAM) and Mesenchymal Stem Cells Derived From Human Umbilical Cord Wharton's Jelly (HUMCWJ) on Pain and Functioning of Knee Osteoarthritis

NCT03337243
View directory record Official record
Conditions
Knee Osteoarthritis, Knee Pain Chronic, Joint Disease, Arthritis, Osteo Arthritis Knee, Musculoskeletal Disease
Interventions
HAM and HUMCWJ Injections
Procedure
Lead sponsor
Sport and Spine Rehab Clinical Research Foundation
Other
Eligibility
50 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 17, 2026, 11:13 AM EDT
Completed Phase 1 Interventional

Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted Myocardium

NCT00548613
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Arteriosclerosis, Coronary Atherosclerosis, Coronary Disease
Interventions
MESENDO
Biological
Lead sponsor
TCA Cellular Therapy
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Covington, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Oct 17, 2026, 11:13 AM EDT
Completed Phase 1 Interventional

Tacrolimus Toothpaste for Management of Oral Chronic Graft vs. Host Disease (cGVHD)

NCT06638879
View directory record Official record
Conditions
Chronic Graft Versus Host Disease Oral
Interventions
Tacrolimus
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 40 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 17, 2026, 11:13 AM EDT
Terminated Phase 2 Interventional Results available

PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma

NCT00240162
View directory record Official record
Conditions
Multiple Myeloma
Interventions
PTK787/ZK 222584
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Oct 17, 2026, 11:13 AM EDT
Completed Phase 2 Interventional Results available

CT-011 MAb in DLBCL Patients Following ASCT

NCT00532259
View directory record Official record
Conditions
Lymphoma, Large Cell, Diffuse, Lymphoma, Mixed Cell, Diffuse, Primary Mediastinal Large B-Cell Lymphoma
Interventions
CT-011
Drug
Lead sponsor
CureTech Ltd
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
20
States / cities
La Jolla, California • San Diego, California • Atlanta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2014 · Synced Oct 17, 2026, 11:13 AM EDT
Not listed Phase 2 Interventional

Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant

NCT00472329
View directory record Official record
Conditions
Graft Failure
Interventions
Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors, fludarabine, TBI
Procedure · Drug
Lead sponsor
Colorado Blood Cancer Institute
Other
Eligibility
18 Years to 74 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Oct 17, 2026, 11:13 AM EDT
Terminated Phase 1 Interventional

Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies

NCT02985554
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Nivolumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Oct 17, 2026, 11:13 AM EDT
Withdrawn Phase 2 Interventional

Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD

NCT05333029
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Allogeneic mesenchymal stromal cells (MSCs), Extracorporeal photopheresis (ECP)
Biological
Lead sponsor
Molly Gallogly
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 17, 2026, 11:13 AM EDT
Terminated Phase 2 Interventional Results available

Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen

NCT02199041
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Cyclophosphamide, Thiotepa, Fludarabine, Melphalan, Mesna, G-CSF, Mycophenolate mofetil, Tacrolimus, Methylprednisolone, Total lymphoid irradiation, Lymphocyte infusions, CliniMACS
Drug · Biological · Radiation + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 17, 2026, 11:13 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients

NCT01769170
View directory record Official record
Conditions
CMV
Interventions
Brincidofovir, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
39
States / cities
La Jolla, California • Los Angeles, California • Denver, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 17, 2026, 11:13 AM EDT
Recruiting No phase listed Observational

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

NCT01890486
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Germ Cell Neoplasms, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Immunodeficiency Diseases
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 17, 2026, 11:13 AM EDT